News 

May 23, 2023

Avalyn Pharma Made Corporate and Clinical Presentations at ATS 2023 Including Results of Long-Term Treatment of Pulmonary Fibrosis with AP01
Read more »

May 11, 2023

Avalyn Pharma Showcasing Therapeutic Approach and Clinical Status at ATS 2023 and the Respiratory Innovation Summit (RIS)
Read more »

May 10, 2023

Avalyn Pharma Presenting at BioEquity Europe
Read more »

April 11, 2023

Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis
Read more »

March 30, 2023

Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis
Read more »

March 23, 2023

Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile
Read more »

November 28, 2022

Avalyn Pharma Invited to Participate in the Annual Evercore ISI HealthCONx Conference
Read more »

October 17, 2022

Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer
Read more »

October 27, 2021

Marc Schneebaum Joins Avalyn Pharma as Chief Financial Officer
Read more »

May 24, 2021

Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial
Read more »

October 16, 2020

Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial
Read more »

April 27, 2020

Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio
Read more »

May 15, 2017

Genoa Pharmaceuticals Secures $62 Million Series A Financing, Adds to Leadership Team
Read more »

October 31, 2016

IPF Up and Comers Look to Add On Rather Than Compete
Read more »

September 3, 2014

Will Little-Known Company’s Inhaled Candidate Take Down InterMune-Roche’s Pirfenidone?
Read more »

August 5, 2014

Genoa Pharmaceuticals Receives Orphan-Drug Designation for Pirfenidone in the Inhaled Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Read more »

May 13, 2014

Genoa Pharmaceuticals to Present at the Annual American Thoracic Society International Conference
Read more »

April 21, 2014

Genoa Pharmaceuticals and McMaster University Demonstrate Inhaled Pharmacokinetics Enables Improved Pirfenidone Activity With Significant Promise to Enhance IPF Treatment Safety and Tolerability
Read more »

June 5, 2013

Genoa Pharmaceuticals and McMaster University Demonstrate in Vivo Benefit of Inhaled Pirfenidone Offering Greater Pulmonary Fibrosis Efficacy Than Oral Therapy
Read more »

January 16, 2013

Genoa Pharmaceuticals and McMaster University to Collaborate on Idiopathic Pulmonary Fibrosis Research
Read more »